Difference between revisions of "Mitiglinide"

Jump to: navigation, search
m (1 revision(s))
Line 1: Line 1:
 +
{{Editor Help}}
 +
 
{{drugbox
 
{{drugbox
 
| IUPAC_name = (-)-2(''S'')-Benzyl-4-(cis-perhydroisoindol-2-yl)butyric acid
 
| IUPAC_name = (-)-2(''S'')-Benzyl-4-(cis-perhydroisoindol-2-yl)butyric acid
Line 37: Line 39:
  
 
[[Category:Meglitinides]]
 
[[Category:Meglitinides]]
 +
 +
{{WikiDoc Help Menu}}
 +
{{WikiDoc Sources}}

Revision as of 16:19, 15 February 2008

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Mitiglinide
Mitiglinide.svg
Clinical data
Routes of
administration
oral
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H25NO3
Molar mass315.41 g/mol

Mitiglinide (trade name Glufast®) is a drug for the treatment of type 2 diabetes.

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

External links



Linked-in.jpg